Google
CINGW Stock Analysis — CINGULATE INC. WARRANTS
CINGW FAQ
What is CINGW's ROE?
CINGULATE INC. WARRANTS reports a Return on Equity (ROE) of -146.91%.
What is CINGW's dividend yield?
CINGULATE INC. WARRANTS offers a dividend yield of 0.00%.
What is CINGW's Quality Score?
Our AI rates CINGW's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CINGW?
Our AI Timing Score for CINGW is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
CINGW AI Analysis Summary
Our AI summary for CINGW: CINGULATE INC. WARRANTS (NASDAQ). The stock currently trades at a P/E of 0.00, ROE of -146.91%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 0/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.01
Price
0.00
(5.60%)
Day Change
|
|
|---|
CINGW, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.01 |
| PBV / Sector |
N/A / N/A
|
| Earning Per Share | N/A |
| PE / Sector |
N/A / N/A
|
| PEG or PE/Growth / Sector |
N/A / N/A
|
| Average 1M Daily Value |
185.435395000000
|
| Average 1W Daily Value |
389.013160000000
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1901 West 47th Place, Kansas City, KS, United States, 66205
Phone: 913 942 2300
Website: https://www.cingulate.com
Sector: -
Description: Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
